Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A close up of a gloved hands holding equipment while carrying out work in a lab.

Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, is collaborating with the University of Oxford and the University of Sheffield on DC-MACS, an investigator led, Phase 2 clinical study in the UK of clofutriben (SPI-62) for the treatment of autonomous cortisol secretion (ACS).

ACS is a prevalent and serious condition caused by the overproduction of cortisol from a benign tumour of the adrenal gland. This study is being conducted with funding from the Medical Research Council. Sparrow is supplying its lead product, clofutriben, and placebo.

The study will be led by RDM's Professor Jeremy Tomlinson and University of Sheffield Professor John Newell-Price. Professor Tomlinson is supported by the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre and the study will be conducted jointly in the NIHR supported clinical research facilities in both Oxford and Sheffield.

'In partnering with Sparrow for the DC-MACS trial, we hope to pioneer a completely novel intervention for this common, yet serious disease', says Professor Tomlinson. 'If successful, this trial could provide patients with ACS with a treatment that could transform their health and quality of life.'

'ACS today usually goes undiagnosed,' explains Professor John Newell-Price. 'This leaves many patients at risk of morbidity from their hypercortisolism, including cardiovascular disease and bone fractures, and even a higher risk of death. Hopefully, we can not only demonstrate a new potential treatment, but also raise awareness of this dangerous disease.'

The objectives of the randomised, double-blind, placebo-controlled study are to evaluate the efficacy, safety, and pharmacological effects of clofutriben, a novel, highly potent, and selective HSD-1 inhibitor, for treating ACS. HSD-1, an intracellular enzyme, activates cortisol in target tissues in which cortisol excess is associated with morbidity including liver, adipose, muscle, and brain. This study will also evaluate endocrine markers such as insulin sensitivity, glucose disposal, and triglycerides during a hyperinsulinemic-euglycemic clamp, nighttime blood pressure, and bone biomarkers (osteocalcin, P1NP, CTX). Forty patients across two sites (Sheffield Teaching Hospitals NHS Foundation Trust and Oxford University Hospitals NHS Foundation Trust) will take part in the study.

'Clofutriben substantially lowers intracellular cortisol, which can bind intracellular receptors and thereby cause the morbidity associated with ACS,' says David Katz, Chief Scientific Officer of Sparrow. 'Clofutriben has potential to be the first targeted therapy for that common, serious, and currently underrecognised disease.'